Эктоин – микробный метаболит с уникальными биотерапевтическими свойствами
Кочеровец В.И. Эктоин – микробный метаболит с уникальными биотерапевтическими свойствами. Педиатрия. Consilium Medicum. 2019; 1: 108–115.
DOI: 10.26442/26586630.2019.1.190314
________________________________________________
Kocherovets V.I. Ectoine – a microbial metabolite with unique biotherapeutic properties. Pediatrics. Consilium Medicum. 2019; 1: 108–115.
DOI: 10.26442/26586630.2019.1.190314
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Объективно оценить практическое значение клинико-фармакологических и фармацевтических характеристик изделий и препаратов на основе эктоина невозможно без глубокого анализа всех обстоятельств, при которых происходит реализация терапевтического эффекта этого микробного метаболита. Следовательно, с одной стороны, необходимо уделить должное внимание коже и слизистым оболочкам как особым биологическим мишеням для молекул эктоина. С другой стороны, нельзя недооценить уникальность эктоинсодержащих протективных средств, направленных на предупреждение и купирование проявлений патологических процессов и симптомов при различных состояниях и заболеваниях респираторной системы, желудочно-кишечного тракта и кожи. Вместе с тем применение разнообразных коммерческих продуктов в медицине и косметологии по-прежнему происходит в условиях, когда механизм действия эктоина не до конца понятен. При указанных обстоятельствах необходимую ясность могут внести результаты новых клинико-экспериментальных исследований метаболитов группы эктоина. Эти данные должны усилить позиции эктоина и его производных как эффективных и безопасных терапевтических средств для медицинского и косметического применения.
Ключевые слова: терапевтические средства для местного применения, микробные метаболиты, эктоин, формы выпуска.
________________________________________________
Objectively assess the practical importance of the clinical, pharmacological and pharmaceutical characteristics of products and preparations based on ectoine is impossible without a deep analysis of all the circumstances in which the therapeutic effect of this microbial metabolite occurs. Therefore, on the one hand, it is necessary to pay due attention to the skin and mucous membranes as special biological targets for ectoin molecules. On the other hand, one cannot underestimate the uniqueness of ectoin-containing protective agents aimed at preventing and arresting the manifestations of pathological processes and symptoms in various conditions and diseases of the respiratory system, gastrointestinal tract and skin. At the same time, the use of various commercial products in medicine and cosmetology still occurs under conditions when the mechanism of action of ectoine is not fully understood. Under these circumstances, the necessary clarity can brought out by the results of new clinical and experimental studies of metabolites of the group of ectoine. These data should strengthen the position of ectoine and its derivatives as effective and safe therapeutic agents for medical and cosmetic use.
Key words: therapeutic agents for local use, microbial metabolites, ectoine, release forms.
assets/uploaded/d141da1f-b538-49f2-b4ca0b04ac5c0b73.pdf
2. Нетрусов А.И., Котова А.Б. Общая микробиология: учеб. М.: Академия, 2007.
[Netrusov A.I., Kotova A.B. Obshchaia mikrobiologiia: ucheb. Moscow: Akademiia, 2007 (in Russian).]
3. Durvasala R, Subba Rao DV. Extremophiles: nature`s amazing adapters. In: Extremophiles: from biology to biotechnology. Ed. by R Durvasala, DV Subba Rao. Boca Raton: CRC Press, 2018; p. 1–17.
4. Encyclopedia of Microbiology. Ed. by M Schaechter. Vol 1. Third edition. Academic Press, 2009.
5. Galinski EA, Pfeiffer HP, Truper HG. 1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic acid. A novel cyclic amino acid from halophilic phototrophic bacteria of the genus Ectothiorhodospira. Eur J Biochem 1985; 149 (1): 135–9.
6. Oren A. Life at high salt concentrations. In: Procaryotes. A handbook on biology of bacteria. Ed. by M Dworkin, S Falkow et al. Third edition. Springer Science + Business Media, LLC, 2006; p. 263–82.
7. Jrwin JA. Medical utility of extremophiles. In: Extremophiles: from biology to biotechnology. Ed. by Durvasala R, DV Subba Rao. Boca Raton: CRC Press, 2018; p. 315–40.
8. Oren А. Industrial and environmental applications of halophilic microorganisms. Environ Technol 2010; 31: 8-9, 825–34. DOI: 10.1080/09593330903370026
9. Bownik A, Stępniewska Z. Ectoine as a promising protective agent in humans and animals. Arh Hig Rada Toksikol 2016; 67: 260–5. Mini-review DOI: 10.1515/aiht-2016-67-2837
10. Galinski EA. Osmoadaptation in bacteria. Adv Microb Physiol 1995; 37: 273–328.
11. Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys J 1985; 47 (3): 411–4.
12. Решетников А.С., Хмеленина В.Н., Троценко Ю.А. Идентификация генов синтеза эктоина у умеренно галофильной альфапротеобактерии Methylarcula marina. Микробиология. 2010; 79 (6): 859–60.
[Reshetnikov A.S., Khmelenina V.N., Trotsenko Iu.A. Identifikatsiia genov sinteza ektoina u umerenno galofil'noi al'faproteobakterii Methylarcula marina. Mikrobiologiia. 2010; 79 (6): 859–60 (in Russian).]
13. Качаев З.М. Идентификация генов биосинтеза эктоина у метилотрофной бактерии Methylarcula marina. Магистерская дис. Пущино, 2010. https://works.doklad.ru/view/S-k7aT8_2KQ/all.html=9.04.19
[Kachaev Z.M. Identifikatsiia genov biosinteza ektoina u metilotrofnoi bakterii Methylarcula marina. Magisterskaia dis. Pushchino, 2010 https://works.doklad.ru/
view/S-k7aT8_2KQ/all.html=9.04.19 (in Russian).]
14. Bergey`s Manual of Systematic Bacteriology. Second Edition, vol. 2. The Proteobacteria Part B. The Gammaproteobacteria. Ed. by DJ Brenner, NR Krieg, JT Staley. Springer, 2005.
15. Намеdi J, Mohammadipanah F, Ventosa A. Systematic and biotechnological aspects of halophilic and halotolerant actinomycetes. Extremophiles 2013; 17 (1): 1–13.
16. Pastor JM, Salvador M, Argandona M et al. Ectoines in cell stress protection: Uses and biotechnological production. Biotechnol Adv 2010; 28: 782–801.
17. Шмарева М.Н. Новые аэробные метилотрофные бактерии из соленых биотопов. Дис. … канд. биол. наук. Пущино, 2016. http://www.dslib.net/micro-biology/novye-ajerobnye-metilotrofnye-bakterii-iz-solenyh-biotopov.html=9...
[Shmareva M.N. Novye aerobnye metilotrofnye bakterii iz solenykh biotopov. Dis. … kand. biol. nauk. Pushchino, 2016 (in Russian).]
18. Da Costa MS, Santos H, Galinsky EA. An overview of the role and diversity of compatible solutes in Bacteria and Archaea. Adv Biochem Eng Biotecnol 1998; 61: 117–53.
19. Czech L, Hermann L, Stöveken N et al. Role of the Extremolytes Ectoine and Hydroxyectoine as Stress Protectants and Nutrients: Genetics, Phylogenomics, Biochemistry, and Structural Analysis. Genes 2018; 9: 177; DOI: 10.3390/genes9040177
20. Knapp S, Ladenstein R, Galinski EA. Extrinsic protein stabilization by the naturally occurring osmolytes beta-hydroxyectoine and betaine. Extremophiles 1999; 3: 191–8.
21. Kurz M. Compatible solute influence on nucleic acids: Many questions but few answers. Saline Syst 2008; 4: 6.
22. Barth S, Huhn M, Matthey B et al. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000; 66: 1572–9.
23. Kolp S, Pietsch M, Galinski EA, Gütschow M. Compatible solutes as protectants for zymogens against proteolysis. Biochim Biophys Acta 2006; 1764: 1234–42. DOI: 10.1016/j.bbapap.2006.04.015
24. Bestvater T, Louis P, Galinski EA. Heterologous ectoine production in Escherichia coli: by-passing the metabolic bottle-neck. Saline Systems 2008; 4: 12. DOI: 10.1186/1746-1448-4-12
25. Schubert T, Maskow T, Benndorf D et al. Continuous synthesis and excretion of the compatible solute ectoine by a transgenic, nonhalophilic bacterium. Appl Environ Microbiol 2007; 73: 3343–7.
26. Moghaieb REA, Tanaka N, Saneoka H et al. Characterization of salt tolerance in ectoine-transformed tobacco plants (Nicotiana tabaccum): photosynthesis, osmotic adjustment, and nitrogen partitioning, Plant Cell Environ 2006; 29: 173–82.
27. Sauer T, Galinski EA. Bacterial milking: a novel bioprocess for production of compatible solutes. Biotechnol Bioengin 1998; 57: 306–13.
28. Frings E, Sauer T, Galinski EA. Production of hydroxyectoin: High cell-density cultivation and osmotic down shocks of Marinococcus strain M52. J Biotechnol 1995; 43: 54–61.
29. https://www.pharmawiki.ch/wiki/index.php?wiki=Ectoin=9.7.18.
30. Roychoudhry A, Bieker A, Häussinger D, Oesterhelt F. Membrane protein stability depends on the concentration of compatible solutes – a single molecule force spectroscopic study. Biol Chem 2013; 394: 1465–74. DOI: 10.1515/hsz-2013-0173
31. Lippert K, Galinski EA. Enzyme stabilization be ectoine-type compatible solutes: protection against heating, freezing and drying. Appl Microbiol Biotechnol 1992; 37:61-5. DOI: 10.1007/BF00174204
32. Zhang L, Wang Y, Zhang C et al. Supplementation effect of ectoine on thermostability of phytase. J Biosci Bioeng 2006; 102: 560–3. DOI: 10.1263/jbb.102.560
33. Lapidot A, Ben-Asher E, Eisenstein M. Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro. FEBS Lett 1995; 367: 33–8. DOI: 10.1016/0014-5793(95)00514-A
34. Tanne C, Golovina EA, Hoekstra FA et al. Glass-forming property of hydroxyectoine is the cause of its superior function as a desiccation protectant. Front Microbiol 2014; 5: 150. DOI: 0.3389/fmicb.2014.00150
35. Cruz PE, Silva AC, Roldão A et al. Screening of novel excipients for improving the stability of retroviral and adenoviral vectors. Biotechnol Prog 2006; 22: 568–76. DOI: 10.1021/bp050294y
36. Unfried K, Kroker M, Autengruber A et al. The compatible solute ectoine reduces the exacerbating effect of environmental model particles on the immune response of the airways. J Allergy Volume 2014; Article ID 708458. http://dx.doi.org/
10.1155/2014/708458
37. https://clinicaltrials.gov/ct2/show/NCT01471184=1.09.18
38. Eichel A, Bilstein A, Werkhauser N, Mosges R. Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis. J Allergy 2014; Article ID 292545. http://dx.doi.org/10.1155/2014/292545
39. Werkhauser N, Bilstein A, Sonnemann U. Treatment of allergic rhinitis with ectoine containing nasal spray in comparison with azelastatine containing nasal spray and eye drops or with cromoglycic acid contaiting nasal spray. J Allergy 2014; Article ID 176597. http://dx.doi.org/10.1155/2014/176597
40. Рязанцев С.В. Барьерная терапия – новое направление в лечении аллергического ринита. Рос. оториноларингология. 2014; 2: 148–53.
[Riazantsev S.V. Bar'ernaia terapiia – novoe napravlenie v lechenii allergicheskogo rinita. Ros. otorinolaringologiia. 2014; 2: 148–53 (in Russian).]
41. Минаева Н.В., Ширяева Д.М. Сравнительная оценка эффективности лечения детей с сезонным аллергическим ринитом антигистаминным препаратом в комбинации с назальным спреем на основе эктоина и монотерапии антигистаминным препаратом: результаты открытого рандомизированного исследования. Вопр. современ. педиатрии. 2015; 14 (4): 483–8. https://doi.org/10.15690/vsp.v14.i4.1387
[Minaeva N.V., Shiriaeva D.M. Sravnitel'naia otsenka effektivnosti lecheniia detei s sezonnym allergicheskim rinitom antigistaminnym preparatom v kombinatsii s nazal'nym spreem na osnove ektoina i monoterapii antigistaminnym preparatom: rezul'taty otkrytogo randomizirovannogo issledovaniia. Vopr. sovremen. pediatrii. 2015; 14 (4): 483–8 (in Russian).]
42. Кайб И.Д., Петрушина А.Д., Майер Е.Ю. и др. Клиническая эффективность препарата Аква Марис® Сенс у детей и подростков с аллергическим ринитом. Педиатрия. 2016; 95 (6): 101–4.
[Kaib I.D., Petrushina A.D., Maier E.Iu. et al. Klinicheskaia effektivnost' preparata Akva MarisR Sens u detei i podrostkov s allergicheskim rinitom. Pediatriia. 2016; 95 (6): 101–4 (in Russian).]
43. Барденикова С.И., Зайцева О.В., Снитко С.Ю. и др. Эффективность барьерной терапии назальным спреем Аква Марис® Сенс у детей с круглогодичным аллергическим ринитом. Педиатрия. 2016; 95 (2): 113–23.
[Bardenikova S.I., Zaitseva O.V., Snitko S.Iu. et al. Effektivnost' bar'ernoi terapii nazal'nym spreem Akva MarisR Sens u detei s kruglogodichnym allergicheskim rinitom. Pediatriia. 2016; 95 (2): 113–23 (in Russian).]
44. Камаев А.В., Трусова О.В. Клиническая эффективность эктоина (ANS01) в форме назального спрея (препарат Аква Марис Сенс) в комплексной терапии персистирующего аллергического ринита у детей и подростков. Рос. оториноларингология. 2015; 4: 131–43.
[Kamaev A.V., Trusova O.V. Klinicheskaia effektivnost' ektoina (ANS01) v forme nazal'nogo spreia (preparat Akva Maris Sens) v kompleksnoi terapii persistiruiushchego allergicheskogo rinita u detei i podrostkov. Ros. otorinolaringologiia. 2015; 4: 131–43 (in Russian).]
45. Мокроносова М.А., Желтикова Т.М., Арефьева А., Тарасова Г.Д. Терапевтический эффект препарата Аква Марис Сенс у больных с аллергическим интермиттирующим ринитом. Рос. оториноларингология. 2017; 2: 142–8.
[Mokronosova M.A., Zheltikova T.M., Aref'eva A., Tarasova G.D. Terapevticheskii effekt preparata Akva Maris Sens u bol'nykh s allergicheskim intermittiruiushchim rinitom. Ros. otorinolaringologiia. 2017; 2: 142–8 (in Russian).]
46. http://www.ectoin.net/index.php/EN/anwendung/=1.9.18
47. Graf R, Anzali S, Buenger J et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 2008; 26: 326–33. DOI: 10.1016/j.clindermatol.2008.01.002
48. Beyer N, Driller H, Bünger J. Ectoine – a innovative, multi-functional active substance for the cosmetic industry. Seifen Öle Fette Wachse J 2000; 126: 26–9.
49. Chao Yuan. Exploratory research for pathogenesis of papulopustular rosacea and skin barrier research in Besançon and Shanghai. Dermatology. Université Bourgogne Franche-Comté, 2017. https://tel.archives-ouvertes.fr/tel-01767270/document=9.04.19
50. Marini A, Reinelt K, Krutmann J, Bilstein A. Ectoine – containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol 2014; 27: 57–65. DOI: 10.1159/000351381
51. Botta C, Di Giorgio C, Sabatier AS, De Meo M. Genotoxicity of visible light (400-800 nm) and photoprotection assessment of ectoin, L-ergothioneine and mannitol and four sunscreens. J Photochem Photobiol 2008; 91: 24–34. DOI: 10.1016/j.jphotobiol.2008.01.008
52. Buenger J, Driller H. Ectoin: An effective natural substance to prevent UVA-induced premature photoaging. Skin Pharmacol Physiol 2004; 17: 232–7. DOI: 10.1159/000080216
53. Idson B. Moisturizers, emollients and bath oils. In: Principles of cosmetics for the dermatologist. Ed. by: P Frost, SN Horwitz. St.Loius, MO: CV Mosby, 1982; p. 37–40.
54. Lynde CW. Moisturizers: What They Are And How They Work. Skin Therapy Letter 2001:6 N 13 December 1. http://www.skintherapyletter.com/eczema/how-moisturizers-work/=8.10.18
55. Hannon CW, Maibach HI. Efficacy of moisturizers assessed through bioengineering techniques. In: Textbook of cosmetic dermatology. Ed. by R Baran, HI Maibach.
3-ed ed. London: Taylor & Francis, 2005; p. 573–612.
56. Seite S, Bieber Т. Barrier function and microbiotic dysbiosis in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology 2015; 8: 479–83.
57. Wollina U. Microbiome in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology 2017; 10: 51–6.
58. Scientific Information: Ectoin the natural stress-protecting molecule. Bitop AG, Germany. http://www.ectoin.net/data/download/bitop_basisbroschuere.pdf
59. Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol 2016; 17: 425–43. http://dx.doi.org/10.1007/s40257-016-0205-5
________________________________________________
1. Microbiology Today May 16, 2016. https://www.microbiologysociety.org/uploads/
assets/uploaded/d141da1f-b538-49f2-b4ca0b04ac5c0b73.pdf
2. Netrusov A.I., Kotova A.B. Obshchaia mikrobiologiia: ucheb. Moscow: Akademiia, 2007 (in Russian).
3. Durvasala R, Subba Rao DV. Extremophiles: nature`s amazing adapters. In: Extremophiles: from biology to biotechnology. Ed. by R Durvasala, DV Subba Rao. Boca Raton: CRC Press, 2018; p. 1–17.
4. Encyclopedia of Microbiology. Ed. by M Schaechter. Vol 1. Third edition. Academic Press, 2009.
5. Galinski EA, Pfeiffer HP, Truper HG. 1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic acid. A novel cyclic amino acid from halophilic phototrophic bacteria of the genus Ectothiorhodospira. Eur J Biochem 1985; 149 (1): 135–9.
6. Oren A. Life at high salt concentrations. In: Procaryotes. A handbook on biology of bacteria. Ed. by M Dworkin, S Falkow et al. Third edition. Springer Science + Business Media, LLC, 2006; p. 263–82.
7. Jrwin JA. Medical utility of extremophiles. In: Extremophiles: from biology to biotechnology. Ed. by Durvasala R, DV Subba Rao. Boca Raton: CRC Press, 2018; p. 315–40.
8. Oren А. Industrial and environmental applications of halophilic microorganisms. Environ Technol 2010; 31: 8-9, 825–34. DOI: 10.1080/09593330903370026
9. Bownik A, Stępniewska Z. Ectoine as a promising protective agent in humans and animals. Arh Hig Rada Toksikol 2016; 67: 260–5. Mini-review DOI: 10.1515/aiht-2016-67-2837
10. Galinski EA. Osmoadaptation in bacteria. Adv Microb Physiol 1995; 37: 273–328.
11. Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys J 1985; 47 (3): 411–4.
12. Reshetnikov A.S., Khmelenina V.N., Trotsenko Iu.A. Identifikatsiia genov sinteza ektoina u umerenno galofil'noi al'faproteobakterii Methylarcula marina. Mikrobiologiia. 2010; 79 (6): 859–60 (in Russian).
13.Kachaev Z.M. Identifikatsiia genov biosinteza ektoina u metilotrofnoi bakterii Methylarcula marina. Magisterskaia dis. Pushchino, 2010 https://works.doklad.ru/
view/S-k7aT8_2KQ/all.html=9.04.19 (in Russian).
14. Bergey`s Manual of Systematic Bacteriology. Second Edition, vol. 2. The Proteobacteria Part B. The Gammaproteobacteria. Ed. by DJ Brenner, NR Krieg, JT Staley. Springer, 2005.
15. Намеdi J, Mohammadipanah F, Ventosa A. Systematic and biotechnological aspects of halophilic and halotolerant actinomycetes. Extremophiles 2013; 17 (1): 1–13.
16. Pastor JM, Salvador M, Argandona M et al. Ectoines in cell stress protection: Uses and biotechnological production. Biotechnol Adv 2010; 28: 782–801.
17. http://www.dslib.net/micro-biology/novye-ajerobnye-metilotrofnye-bakterii-iz-solenyh-biotopov.html=9...Shmareva M.N. Novye aerobnye metilotrofnye bakterii iz solenykh biotopov. Dis. … kand. biol. nauk. Pushchino, 2016 (in Russian).
18. Da Costa MS, Santos H, Galinsky EA. An overview of the role and diversity of compatible solutes in Bacteria and Archaea. Adv Biochem Eng Biotecnol 1998; 61: 117–53.
19. Czech L, Hermann L, Stöveken N et al. Role of the Extremolytes Ectoine and Hydroxyectoine as Stress Protectants and Nutrients: Genetics, Phylogenomics, Biochemistry, and Structural Analysis. Genes 2018; 9: 177; DOI: 10.3390/genes9040177
20. Knapp S, Ladenstein R, Galinski EA. Extrinsic protein stabilization by the naturally occurring osmolytes beta-hydroxyectoine and betaine. Extremophiles 1999; 3: 191–8.
21. Kurz M. Compatible solute influence on nucleic acids: Many questions but few answers. Saline Syst 2008; 4: 6.
22. Barth S, Huhn M, Matthey B et al. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000; 66: 1572–9.
23. Kolp S, Pietsch M, Galinski EA, Gütschow M. Compatible solutes as protectants for zymogens against proteolysis. Biochim Biophys Acta 2006; 1764: 1234–42. DOI: 10.1016/j.bbapap.2006.04.015
24. Bestvater T, Louis P, Galinski EA. Heterologous ectoine production in Escherichia coli: by-passing the metabolic bottle-neck. Saline Systems 2008; 4: 12. DOI: 10.1186/1746-1448-4-12
25. Schubert T, Maskow T, Benndorf D et al. Continuous synthesis and excretion of the compatible solute ectoine by a transgenic, nonhalophilic bacterium. Appl Environ Microbiol 2007; 73: 3343–7.
26. Moghaieb REA, Tanaka N, Saneoka H et al. Characterization of salt tolerance in ectoine-transformed tobacco plants (Nicotiana tabaccum): photosynthesis, osmotic adjustment, and nitrogen partitioning, Plant Cell Environ 2006; 29: 173–82.
27. Sauer T, Galinski EA. Bacterial milking: a novel bioprocess for production of compatible solutes. Biotechnol Bioengin 1998; 57: 306–13.
28. Frings E, Sauer T, Galinski EA. Production of hydroxyectoin: High cell-density cultivation and osmotic down shocks of Marinococcus strain M52. J Biotechnol 1995; 43: 54–61.
29. https://www.pharmawiki.ch/wiki/index.php?wiki=Ectoin=9.7.18.
30. Roychoudhry A, Bieker A, Häussinger D, Oesterhelt F. Membrane protein stability depends on the concentration of compatible solutes – a single molecule force spectroscopic study. Biol Chem 2013; 394: 1465–74. DOI: 10.1515/hsz-2013-0173
31. Lippert K, Galinski EA. Enzyme stabilization be ectoine-type compatible solutes: protection against heating, freezing and drying. Appl Microbiol Biotechnol 1992; 37:61-5. DOI: 10.1007/BF00174204
32. Zhang L, Wang Y, Zhang C et al. Supplementation effect of ectoine on thermostability of phytase. J Biosci Bioeng 2006; 102: 560–3. DOI: 10.1263/jbb.102.560
33. Lapidot A, Ben-Asher E, Eisenstein M. Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro. FEBS Lett 1995; 367: 33–8. DOI: 10.1016/0014-5793(95)00514-A
34. Tanne C, Golovina EA, Hoekstra FA et al. Glass-forming property of hydroxyectoine is the cause of its superior function as a desiccation protectant. Front Microbiol 2014; 5: 150. DOI: 0.3389/fmicb.2014.00150
35. Cruz PE, Silva AC, Roldão A et al. Screening of novel excipients for improving the stability of retroviral and adenoviral vectors. Biotechnol Prog 2006; 22: 568–76. DOI: 10.1021/bp050294y
36. Unfried K, Kroker M, Autengruber A et al. The compatible solute ectoine reduces the exacerbating effect of environmental model particles on the immune response of the airways. J Allergy Volume 2014; Article ID 708458. http://dx.doi.org/
10.1155/2014/708458
37. https://clinicaltrials.gov/ct2/show/NCT01471184=1.09.18
38. Eichel A, Bilstein A, Werkhauser N, Mosges R. Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis. J Allergy 2014; Article ID 292545. http://dx.doi.org/10.1155/2014/292545
39. Werkhauser N, Bilstein A, Sonnemann U. Treatment of allergic rhinitis with ectoine containing nasal spray in comparison with azelastatine containing nasal spray and eye drops or with cromoglycic acid contaiting nasal spray. J Allergy 2014; Article ID 176597. http://dx.doi.org/10.1155/2014/176597
40. Riazantsev S.V. Bar'ernaia terapiia – novoe napravlenie v lechenii allergicheskogo rinita. Ros. otorinolaringologiia. 2014; 2: 148–53 (in Russian).
41.Minaeva N.V., Shiriaeva D.M. Sravnitel'naia otsenka effektivnosti lecheniia detei s sezonnym allergicheskim rinitom antigistaminnym preparatom v kombinatsii s nazal'nym spreem na osnove ektoina i monoterapii antigistaminnym preparatom: rezul'taty otkrytogo randomizirovannogo issledovaniia. Vopr. sovremen. pediatrii. 2015; 14 (4): 483–8 (in Russian).https://doi.org/10.15690/vsp.v14.i4.1387
42. Kaib I.D., Petrushina A.D., Maier E.Iu. et al. Klinicheskaia effektivnost' preparata Akva MarisR Sens u detei i podrostkov s allergicheskim rinitom. Pediatriia. 2016; 95 (6): 101–4 (in Russian).
43. Bardenikova S.I., Zaitseva O.V., Snitko S.Iu. et al. Effektivnost' bar'ernoi terapii nazal'nym spreem Akva MarisR Sens u detei s kruglogodichnym allergicheskim rinitom. Pediatriia. 2016; 95 (2): 113–23 (in Russian).
44.Kamaev A.V., Trusova O.V. Klinicheskaia effektivnost' ektoina (ANS01) v forme nazal'nogo spreia (preparat Akva Maris Sens) v kompleksnoi terapii persistiruiushchego allergicheskogo rinita u detei i podrostkov. Ros. otorinolaringologiia. 2015; 4: 131–43 (in Russian).
45. Mokronosova M.A., Zheltikova T.M., Aref'eva A., Tarasova G.D. Terapevticheskii effekt preparata Akva Maris Sens u bol'nykh s allergicheskim intermittiruiushchim rinitom. Ros. otorinolaringologiia. 2017; 2: 142–8 (in Russian).
46. http://www.ectoin.net/index.php/EN/anwendung/=1.9.18
47. Graf R, Anzali S, Buenger J et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 2008; 26: 326–33. DOI: 10.1016/j.clindermatol.2008.01.002
48. Beyer N, Driller H, Bünger J. Ectoine – a innovative, multi-functional active substance for the cosmetic industry. Seifen Öle Fette Wachse J 2000; 126: 26–9.
49. Chao Yuan. Exploratory research for pathogenesis of papulopustular rosacea and skin barrier research in Besançon and Shanghai. Dermatology. Université Bourgogne Franche-Comté, 2017. https://tel.archives-ouvertes.fr/tel-01767270/document=9.04.19
50. Marini A, Reinelt K, Krutmann J, Bilstein A. Ectoine – containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol 2014; 27: 57–65. DOI: 10.1159/000351381
51. Botta C, Di Giorgio C, Sabatier AS, De Meo M. Genotoxicity of visible light (400-800 nm) and photoprotection assessment of ectoin, L-ergothioneine and mannitol and four sunscreens. J Photochem Photobiol 2008; 91: 24–34. DOI: 10.1016/j.jphotobiol.2008.01.008
52. Buenger J, Driller H. Ectoin: An effective natural substance to prevent UVA-induced premature photoaging. Skin Pharmacol Physiol 2004; 17: 232–7. DOI: 10.1159/000080216
53. Idson B. Moisturizers, emollients and bath oils. In: Principles of cosmetics for the dermatologist. Ed. by: P Frost, SN Horwitz. St.Loius, MO: CV Mosby, 1982; p. 37–40.
54. Lynde CW. Moisturizers: What They Are And How They Work. Skin Therapy Letter 2001:6 N 13 December 1. http://www.skintherapyletter.com/eczema/how-moisturizers-work/=8.10.18
55. Hannon CW, Maibach HI. Efficacy of moisturizers assessed through bioengineering techniques. In: Textbook of cosmetic dermatology. Ed. by R Baran, HI Maibach.
3-ed ed. London: Taylor & Francis, 2005; p. 573–612.
56. Seite S, Bieber Т. Barrier function and microbiotic dysbiosis in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology 2015; 8: 479–83.
57. Wollina U. Microbiome in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology 2017; 10: 51–6.
58. Scientific Information: Ectoin the natural stress-protecting molecule. Bitop AG, Germany. http://www.ectoin.net/data/download/bitop_basisbroschuere.pdf
59. Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol 2016; 17: 425–43. http://dx.doi.org/10.1007/s40257-016-0205-5
В.И.Кочеровец*
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М.Сеченова». 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*kftif@mail.ru
________________________________________________
Vladimir I. Kocherovets*
I. M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 8, 2 Trubetskaia str., Moscow, 119991, Russian Federation
*kftif@mail.ru